BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16493208)

  • 21. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
    Horinaga M; Fukuyama R; Iida M; Yanaihara H; Nakahira Y; Nonaka S; Deguchi N; Asakura H
    Urology; 2010 Nov; 76(5):1267.e1-6. PubMed ID: 21056277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
    Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
    J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.
    Perdonà S; Di Lorenzo G; Cantiello F; Damiano R; De Sio M; Masala D; Bruni G; Gallo L; Federico P; Quattrone C; Pizzuti M; Autorino R
    Anticancer Drugs; 2010 Jan; 21(1):101-6. PubMed ID: 19858710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.
    Bartoletti R; Cai T; Gacci M; Giubilei G; Viggiani F; Santelli G; Repetti F; Nerozzi S; Ghezzi P; Sisani M;
    Urology; 2005 Oct; 66(4):726-31. PubMed ID: 16230125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guérin (Danish 1331 strain).
    Kulkarni JN; Gupta R
    BJU Int; 2002 Oct; 90(6):554-7. PubMed ID: 12230616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.
    Bassi P; De Marco V; Tavolini IM; Longo F; Pinto F; Zucchetti M; Crucitta E; Marini L; Dal Moro F
    Urol Int; 2005; 75(4):309-13. PubMed ID: 16327296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance.
    Morabito F; Rossi R; Graziano ME; Ferrando U; Lancini V; Cretarola E; Conti G; Luporini AC; Muto G; Castelli E; D'Urso L; Razionale P; Lissoni G; Simone M; Francesca F; Sommariva M; Casu M; Hurle R
    Arch Ital Urol Androl; 2006 Mar; 78(1):1-4. PubMed ID: 16752879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin in superficial bladder cancer: a preliminary study.
    Cho DY; Bae JH; Moon DG; Cheon J; Lee JG; Kim JJ; Yoon DK; Park HS
    J Int Med Res; 2009; 37(6):1823-30. PubMed ID: 20146880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravesical therapy for superficial cancer: need for more options.
    Crawford ED
    J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience.
    Pansadoro V; Emiliozzi P; de Paula F; Scarpone P; Pansadoro A; Sternberg CN
    Urology; 2002 Feb; 59(2):227-31. PubMed ID: 11834391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder.
    Baniel J; Grauss D; Engelstein D; Sella A
    Urology; 1998 Nov; 52(5):785-9. PubMed ID: 9801099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
    Peyromaure M; Zerbib M
    BJU Int; 2004 Jan; 93(1):60-3. PubMed ID: 14678369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
    Lee JY; Diaz RR; Cho KS; Lim MS; Chung JS; Kim WT; Ham WS; Choi YD
    J Urol; 2013 Oct; 190(4):1192-9. PubMed ID: 23648222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.
    Hurle R; Losa A; Manzetti A; Lembo A
    Urology; 1999 Aug; 54(2):258-63. PubMed ID: 10443721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.